Related Experiment Videos
Remoxipride in schizophrenia. A preliminary report
Acta Psychiatrica Scandinavica
|October 1, 1986
Summary
Remoxipride showed clinical improvement in six of ten schizophrenia patients, with mild side effects and decreased extrapyramidal symptoms. This substituted benzamide offers a promising therapeutic option for psychosis.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Schizophrenia is a chronic mental disorder characterized by psychosis.
- Dopaminergic pathways, particularly in the mesolimbic system, are implicated in schizophrenia.
- Novel antipsychotic agents are needed to improve treatment efficacy and tolerability.
Purpose of the Study:
- To investigate the efficacy and tolerability of remoxipride in patients with schizophrenia.
- To assess the effect of remoxipride on psychotic symptomatology and adverse effects.
Main Methods:
- An open-label study involving 10 schizophrenic patients.
- A 1-week placebo period followed by 6 weeks of remoxipride treatment with incrementally increasing doses (150-450 mg/day).
- Clinical assessment using the Brief Psychiatric Rating Scale (BPRS) and monitoring of adverse effects, prolactin, and homovanillic acid (HVA) levels.
Main Results:
- Six out of ten patients experienced a clinically relevant reduction in psychotic symptoms.
- Remoxipride was generally well-tolerated, with mild reported side effects.
- Extrapyramidal symptoms, when present, showed a decrease during treatment.
- No consistent changes in plasma prolactin or HVA levels were observed.
Conclusions:
- Remoxipride demonstrates potential efficacy in treating schizophrenia symptoms.
- The drug appears to have a favorable side effect profile, including a reduction in extrapyramidal symptoms.
- Further research is warranted to confirm these findings in larger, controlled trials.